Navigation Links
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Date:10/15/2010

rogression for Teriflunomide 14mg

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose (p=0.02) and numerically reduced by 24% for the 7mg dose (p=0.08). Both doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) including serious adverse events or TEAEs leading to treatment discontinuation in the treatment vs. placebo arms.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/46556-Sanofi-Aventis-Teriflunomide/

"We are very pleased with the successful results of the TEMSO study which are an important step forward in multiple sclerosis clinical research," said Marc Cluzel, M.D., Ph.D., Executive Vice President, Research & Development, sanofi-aventis. "These exciting results with teriflunomide represent a new real hope to delivering an oral therapy to patients who live with this serious condition and are eager for new treatment options, and more convenient product forms in-line with our sanofi-aventis commitment to multiple sclerosis."

The results of the TEMSO trial are the first study findings from a large phase III clinical development program on teriflunomide. These results were presented today during the European Committee for Treatment and Research in M
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Medisafe 1 Technologies Successfully Tests Prototype of Patented Syringe Locking Device
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
3. Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
4. Omeros Successfully Unlocks Orphan GPCRs
5. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
6. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
7. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
10. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
11. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Cardinal Health will today name three of the nation,s ... Independent Pharmacy Best Practices Competition, during the company,s ... gatherings of independent pharmacists. The Best ... Ohio , Tennessee and ... implementing exceptionally creative methods that demonstrate how independent pharmacies ...
(Date:7/25/2014)... 2014  Solanbridge Group Inc (OTC: SLNX) is pleased ... in Buzznbrewz.com and the Letter of Intent issued on ... executed Purchase Agreement. Charles R. Shirley ... to have Mr. David Pecoraro and Buzznbrewz.com ... the private sector and developed a tremendous network of ...
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4
... Nektar Therapeutics,(Nasdaq: NKTR ) announced ... its pipeline programs will be presented at ... months. These presentations will,highlight Nektar,s novel therapeutic ... central nervous system (CNS), which leverage Nektar,s,innovative ...
... Leading RSV,investigator Dr. John DeVincenzo has taken another ... bronchiolitis and pneumonia,according to the Centers for Disease Control. ... of hospitalization of infants in the US and,one of ... group., DeVincenzo is using the process of RNAi ...
Cached Medicine Technology:Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 2Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 3Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings 4RSV Researcher Makes Gains in Finding Treatments 2
(Date:7/27/2014)... Bags underneath the eyes is one condition that ... are a range of new products now available from Internet ... eyes serum review that is now posted for adults to ... issues with baggy eyes and how the natural ingredients in ... guide also provides a detailed overview of the creams and ...
(Date:7/27/2014)... 27, 2014 Ticket Down is a ... Forum in Inglewood, California on November 15th. This Australian ... can expect to hear songs from this amazing album at the ... in Inglewood, California at The Forum will be released for sale ... a.m. today local time TicketDown.com. This popular secondary ticket exchange ...
(Date:7/27/2014)... University of Manchester have discovered why medication to treat asthma ... Nature Medicine , show that drugs widely used to ... , In the UK pneumonia, which is caused by an ... is more serious for babies, young children, the elderly, smokers ... than 5 million people in the UK are affected by ...
(Date:7/27/2014)... July 27, 2014 The North American ... estimated at $1570 million in 2014, and it is ... CAGR of 4.64%. The report incorporates the factors that ... expectations of growth rates and projected total expenditure. The ... the global markets. Apart from the general overview of ...
(Date:7/27/2014)... The European Agricultural Adjuvants Market report defines and segments ... of revenue. The agricultural adjuvants market in Europe is ... to $657.1 million by 2018, at a CAGR of ... TOC of the European Agricultural Adjuvants Market report, to ... also provides a glimpse of the segmentation in the ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Drugs used to treat lung disease work with the body clock 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Agricultural Adjuvants Market is Expected to Reach $657.1 million in 2018 - New Report by MicroMarket Monitor 5
... The patent expiry of blockbuster molecules ... intense competition from generics. CEOs have had ... to maintain the growth of their organisation ... on the market for niche blockbuster drugs ...
... Peanut Field, Product Sampling March 4 and 5NEW YORK, Feb. ... up shop in Vanderbilt Hall in New York City,s Grand ... questions and give away samples of peanuts, peanut butter and ... efforts nationally to rebuild consumer confidence in products made with ...
... Feb. 25 HealthFitness Corporation (NYSE Alternext ... and productivity management solutions, will conduct a conference call ... and year ended December 31, 2008. The call is ... 2009.Participants can dial (888) 396-5640 or (706) 643-0580 to ...
... N.J., Feb. 25 Psychiatric ... one of the nation,s leading experts in the field ... director of psychiatric drug research at the R/D Clinical ... special interest in the therapeutic areas of depression and ...
... Center for Wellbeing today announced its Chopra en ... Spanish speakers seeking out the Center,s programs and ... and human empowerment.(Photo: http://www.newscom.com/cgi-bin/prnh/20080617/LATU012 )"In the ... I first had the idea to create a ...
... on the future of SBIR grants in Washington, DC as a means ... being explicitly excluded from NIH stimulus money. Federal reauthorization or a continuing ... ... 25, 2009 -- Looking for funding for small business ventures ...
Cached Medicine News:Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 2Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 4Health News:America's Peanut Farmers to Travel to New York City to Meet Consumers, Work to Rebuild Trust in All Things Peanut 2Health News:Psychiatric Congress 2009 Announces Rakesh Jain, MD, MPH, as Program Chair 2Health News:The Chopra Center Introduces Mind-body Health Programs for Spanish Speakers: Chopra en Espanol Connects Spanish Speakers Worldwide to Deepak Chopra and David Simon's Global Message of Wellness 2Health News:The Commercialization Funding Coach, Fred Patterson, Weighs In On SBIR Funding for Small Business Ventures in Wake of NIH Exclusion 2Health News:The Commercialization Funding Coach, Fred Patterson, Weighs In On SBIR Funding for Small Business Ventures in Wake of NIH Exclusion 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: